Who is sponsoring NCT03524261?

NCT03524261 is sponsored by Fuda Cancer Hospital, Guangzhou.

What condition does NCT03524261 study?

NCT03524261 studies Advanced Breast Cancer.

Is NCT03524261 still recruiting?

NCT03524261 is currently withdrawn. Last updated 19 October 2020.

Last reviewed 2020-10-19 · How we verify

NCT03524261

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Breast Cancer

Withdrawn Phase 2 Last updated 19 October 2020

What this trial tests

Phase 2 trial testing Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer in Advanced Breast Cancer. Withdrawn.

Timeline

20 May 2019

Primary endpoint
5 April 2020

5 July 2020

Quick facts

Lead sponsor	Fuda Cancer Hospital, Guangzhou
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Start date	20 May 2019
Primary completion	5 April 2020
Estimated completion	5 July 2020
Sites	1 location across China

Drugs / interventions tested

Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer — full drug profile →
cryotherapy (CRYOTHERAPY) — full drug profile →

Conditions studied

Advanced Breast Cancer — all drugs for Advanced Breast Cancer →

Sponsor

Fuda Cancer Hospital, Guangzhou

Who can join

Adults 18 to 75, any sex, with Advanced Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a phase II Randomized comparison clinical trial of activated CIK armed with anti-CD3-MUC1 bispecific antibody for advanced breast cancer. And the aim of this research is to study the clinical efficacy and safety of activated CIK armed with anti-CD3-MUC1 bispecific antibody for breast cancer.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Glycosylation: mechanisms, biological functions and clinical implications.
He M, Zhou X, Wang X. · · 2024 · cited 248× · PMID 39098853 · DOI 10.1038/s41392-024-01886-1
Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.
Runcie K, Budman DR, John V, Seetharamu N. · · 2018 · cited 120× · PMID 30249178 · DOI 10.1186/s10020-018-0051-4
Overcoming the challenges associated with CD3+ T-cell redirection in cancer.
Singh A, Dees S, Grewal IS. · · 2021 · cited 82× · PMID 33469153 · DOI 10.1038/s41416-020-01225-5
TNBC: Potential Targeting of Multiple Receptors for a Therapeutic Breakthrough, Nanomedicine, and Immunotherapy.
Singh DD, Yadav DK. · · 2021 · cited 76× · PMID 34440080 · DOI 10.3390/biomedicines9080876
Potential of Anti-MUC1 Antibodies as a Targeted Therapy for Gastrointestinal Cancers.
Bose M, Mukherjee P. · · 2020 · cited 40× · PMID 33167508 · DOI 10.3390/vaccines8040659
Bispecific antibodies for the treatment of breast cancer.
Dillon PM, Tushir-Singh J, Lum LG. · · 2022 · cited 11× · PMID 33896311 · DOI 10.1080/14712598.2021.1922665
Advances in MUC1-Mediated Breast Cancer Immunotherapy.
Li Z, Yang D, Guo T, Lin M. · · 2022 · cited 10× · PMID 35883508 · DOI 10.3390/biom12070952
The war between the immune system and the tumor - using immune biomarkers as tracers.
Yang K, Lu R, Mei J, Cao K, et al · · 2024 · cited 9× · PMID 38816871 · DOI 10.1186/s40364-024-00599-5

Verify or expand the search:

Other recruiting trials for Advanced Breast Cancer

Currently open trials in the same condition.

NCT07408089 — Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer · Phase 1 · recruiting
NCT07318805 — A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors · Phase 1 · recruiting
NCT07259226 — Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers · Phase 2 · recruiting
NCT06982521 — Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PI · Phase 3 · recruiting
NCT07428655 — Acceptability and Feasibility of PSC Model of Serious Illness Communication · NA · active not recruiting

Other Fuda Cancer Hospital, Guangzhou trials

Trials by the same sponsor.

NCT04393220 — Combination of PD-1 and VEGFR-2 Blockade for Advanced Hepatocellular Carcinoma · Phase 2 · completed
NCT03673137 — Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC · Phase 2, PHASE3 · completed
NCT03976206 — Very Small Embryonic-like Stem Cells for Facial Skin Antiaging · Phase 1, PHASE2 · withdrawn
NCT03975101 — Very Small Embryonic-like Stem Cells for Knee Osteoarthritis · Phase 1, PHASE2 · withdrawn
NCT03985462 — Very Small Embryonic-like Stem Cells for Ovary · Phase 1, PHASE2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03524261 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fuda Cancer Hospital, Guangzhou
Last refreshed: 19 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03524261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing